| Identification | More | [Name]
Finasteride | [CAS]
98319-26-7 | [Synonyms]
1,(5-ALPHA)-ANDROSTAN-4-AZA-3-ONE-17-BETA-(N-TERT-BUTYL-CARBOXAMIDE)
17BETA-(T-BUTYLCARBAMOYL)-4-AZA-5-ALPHA-ANDROSTEN-3-ONE
4A,6A,11A-TRIMETHYL-2-OXO-2,4A,4B,5,6,6A,7,8,9,9A,9B,10,11,11A-TETRADECAHYDRO-1H-INDENO[5,4-F]QUINOLINE-7-CARBOXYLIC ACID TERT-BUTYLAMIDE
(4AR,4BS,6AS,7S,9AS,9BS,11AR)-4A,6A-DIMETHYL-2-OXO-2,4A,4B,5,6,6A,7,8,9,9A,9B,10,11,11A-TETRADECAHYDRO-1H-INDENO[5,4-F]QUINOLINE-7-CARBOXYLIC ACID TERT-BUTYLAMIDE
FINASTERIDE
FINASTID
MK-906
N-(2-METHYL-2-PROPYL)-3-OXO-4-AZA-5ALPHA-ANDROST-1-ENE-17BETA-CARBOXAMIDE
PROSCAR
PROSTIDE
(5alpha,17beta)-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
17beta-(n-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5-alpha,17-be
4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta
l-652,931
mk-0906
n-tert-butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
N-Tert-Butyl-3-Oxo-4-Aza-5alpha-Androst-1-Ene-17be
Finasteride, Vetranal
FinasterideEdmf/Gmp | [EINECS(EC#)]
620-534-3 | [Molecular Formula]
C23H36N2O2 | [MDL Number]
MFCD00869737 | [Molecular Weight]
372.54 | [MOL File]
98319-26-7.mol |
| Chemical Properties | Back Directory | [Appearance]
Off-White Crystalline Powder | [Melting point ]
253 °C | [alpha ]
405 -59° (c = 1 in methanol) | [Boiling point ]
576.6±50.0 °C(Predicted) | [density ]
1.065±0.06 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO: 32 mg/mL, soluble
| [form ]
solid
| [pka]
14.17±0.70(Predicted) | [color ]
white to beige | [Water Solubility ]
insoluble | [Usage]
Inhibitor of 5a-reductase, the enzyme which converts testosterone to the more potent androgen, 5a-dihydrotestosterone.
Antialopecia agent | [Merck ]
4082 | [BCS Class]
1 | [InChIKey]
DBEPLOCGEIEOCV-WSBQPABSSA-N | [LogP]
3.030 | [CAS DataBase Reference]
98319-26-7(CAS DataBase Reference) | [EPA Substance Registry System]
1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(1,1-dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (98319-26-7) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn,T,Xi | [Risk Statements ]
R22:Harmful if swallowed.
R61:May cause harm to the unborn child.
R60:May impair fertility.
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) .
S53:Avoid exposure-obtain special instruction before use .
S36:Wear suitable protective clothing .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . | [WGK Germany ]
3
| [RTECS ]
CL5245000
| [HS Code ]
29379000 | [Hazardous Substances Data]
98319-26-7(Hazardous Substances Data) |
| Questions And Answer | Back Directory | [Indications and Usage]
Finasteride is a basic drug to treat benign prostatic hyperplasia and prostatitis, a synthetic 4-nitrogen steroid hormone compound and a sex hormone drug.
It is used for benign prostatic hyperplasia, men's prostatic fat and other diseases. Finasteride is the only oral drug approved by the US Food and Drug Administration (FDA) to treat male pattern baldness.
| [Mechanisms of Action]
Finasteride can selectively inhibit 5α-reductase, changing the conversion process of testosterone into 5α dihydrotestosterone (DHT), decreasing androgen levels in prostate cells, and prostate-specific antigens in serum, decreasing prostate swelling, and increasing urine flow rate, thereby alleviating the symptoms of prostatic hyperplasia. It acts by selectively blocking androgen stimulation of the prostate, but affects sexual function very rarely. Meanwhile, due to blocking of testosterone conversion and reduced synthesis of dihydrotestosterone, it can reduce dihydrotestosterone levels in the serum and scalp hair follicles, recovering the function of previously inhibited hair follicles, promoting hair growth and preventing loss. | [clinical trials]
Three controlled clinical trials were performed in men (18 to 41 years), with mild-to-moderate degrees of androgenetic alopecia. In these studies, 1879 men ingested either a 1- mg finasteride tablet or placebo tablet once daily for 12 months; after 12 months, finasteride-treated patients were switched to placebo and placebo-treated patients were switched to finasteride and they were followed for an additional 12 months. Clinical improvement was seen as early as 3 months in finasteride-treated patients and hair regrowth continued throughout the trial. Finasteride also had a stabilizing effect on hair loss, which was maintained through the second year of treatment. Hair counts in placebo-treated patients decreased during the study. Finasteride was generally well tolerated in these studies. Some men, however, experienced decreased libido, difficulty in achieving an erection, and decreased semen volume (<2% of patients in each case). These side effects resolved in 58% of the men who continued treatment and completely abated upon discontinuation of the drug. |
| Hazard Information | Back Directory | [Description]
Finasteride, a novel 4-azasteroid, is a breakthrough in the treatment and control of
benign prostatic hyperplasia. Mechanistically, it inhibits the prostatic-specific enzyme
5-alpha reductase, thereby decreasing the conversion of testosterone to
dihydrotestosterone. It is reportedly effective in reducing urinary symptoms and
prostatic volume and increasing maximal urinary flow rate. Finasteride is also being
investigated as a treatment for prostatic cancer. | [Chemical Properties]
Off-White Crystalline Powder | [Originator]
Merck (U.S.A.) | [Uses]
Finasteride is a specific inhibitor of steroid type II 5α-reductase, an intracellular enzyme that converts testosterone to DHT. By inhibiting type II 5α-reductase, this conversion is blocked, resulting in significant decreases in serum and tissue DHT concentrations. Merck & Co. developed finasteride as an oral treatment for androgenetic alopecia after men taking finasteride (5 mg/ day) for prostate enlargement noticed regrowth of their hair.
Finasteride is indicated for use in men only. Women of childbearing age cannot take finasteride because it may cause hypospadia (a developmental abnormality of the penis) in the male offspring if taken during pregnancy.
| [Uses]
Inhibitor of 5α-reductase, the enzyme which converts testosterone to the more potent androgen, 5α-dihydrotestosterone.
Antialopecia agent. | [Uses]
Treatment of benign prostatic hyperplasia and androgenetic alopecia | [Application]
Finasteride is a specific inhibitor of steroid type II 5α-reductase, an intracellular enzyme that converts testosterone to DHT. By inhibiting type II 5α-reductase, this conversion is blocked, resulting in significant decreases in serum and tissue DHT concentrations. Merck & Co. developed finasteride as an oral treatment for androgenetic alopecia after men taking finasteride (5 mg/ day) for prostate enlargement noticed regrowth of their hair. Finasteride is indicated for use in men only. Women of childbearing age cannot take finasteride because it may cause hypospadia (a developmental abnormality of the penis) in the male offspring if taken during pregnancy. | [Definition]
ChEBI: An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia. | [Indications]
Finasteride (Proscar) is a 5-reductase inhibitor that
blocks the conversion of testosterone to DHT in target
tissues. Since DHT is the major intracellular androgen
in the prostate, finasteride is effective in suppressing
DHT stimulation of prostatic growth and secretory
function without markedly affecting libido. It is approved
for the treatment of benign prostatic hyperplasia.
Although there is usually some regression in the size
of the prostate gland following administration of finasteride,
clinical response may take 6 to 12 months. If the
obstructive symptoms are severe, there is often not
enough time to allow this compound to work.The principal
adverse effects of finasteride are impotence, decreased
libido, and decreased volume of ejaculate. The
compound is generally well tolerated in men. | [Manufacturing Process]
In a flask equipped with an overhead stirrer, a nitrogen inlet, and reflux
condenser was placed 840 ml of dry THF and 20.0 g of 17β-carboxylate 17β-
carbomethoxy ester of 4-aza-5α-androst-1-en-3-one (synthesized according to Patent US 4,377,584, issued Mar. 22,1883, and J. Med. Chem., 29, 2298
(1986)). The resulting slurry was cooled to -5-10°C, and 27.6 mL of tbutylamine
was added. A solution of ethylmagnesium bromide in THF (122
mL, 2 M) was added maintaining the temperature of the reaction mixture
below 10°C. The reaction mixture was heated at reflux for 12 hours and was
added to a cold (10°C) solution of 25% ammonium chloride in water. The
mixture was warmed to 25°C and allowed to settle. The THF solution was
separated and concentrated by atmospheric distillation to 200 mL and the
product was crystallized by adding approximately 600 mL of dilute aqueous
HCl. The resulting white solid was isolated by filtration and was dried at 70°C
under vacuum to give 21.7 g (97% yield) 2-butyl-1-(4-carboxybenzyl)-4-
chloroimidazole-5-acetic acid of finasteride. The finasteride can be purified by
conventional procedures, e.g. recrystallization from methylene chloride/ethyl
acetate or acetic acid/water, melting point 261°C. | [Brand name]
Proscar | [Therapeutic Function]
Antineoplastic | [Biological Activity]
Antiandrogen that inhibits type II 5 α reductase (IC 50 = 65 nM). Suppresses the conversion of testosterone to dihydrotestosterone. Reduces prostatic dihydrotestosterone levels and prostate size in vivo . Orally active. | [Biochem/physiol Actions]
Selective 5α-reductase inhibitor; antiandrogen. | [Pharmacokinetics]
The mean oral bioavailability of finasteride is 65%, as shown in Table 45.4, and is not affected by food. Approximately 90% of circulating finasteride is bound to plasma proteins. Finasteride has been found to cross the blood-brain barrier, but levels in semen were undetectable (<0.2 ng/mL). Finasteride is extensively metabolized in the liver, primarily via CYP3A4 to two major metabolites: monohydroxylation of the t-butyl side chain, which is further metabolized via an aldehyde intermediate to the second metabolite, a monocarboxylic acid. The metabolites show approximately 20% the inhibition of finasteride for 5α-reductase. The mean terminal half-life is approximately 5 to 6 hours in men between 18 and 60 years of age and 8 hours in men older than 70 years of age. Following an oral dose of finasteride, approximately 40% of the dose was excreted in the urine as metabolites and approximately 57% in the feces. Even though the elimination rate of finasteride is decreased in the elderly, no dosage adjustment is necessary. No dosage adjustment is necessary in patients with renal insufficiency. A decrease in the urinary excretion of metabolites was observed in patients with renal impairment, but this was compensated for by an increase in fecal excretion of metabolites. Caution should be used during administration to patients with liver function abnormalities, because finasteride is metabolized extensively in the liver. | [Clinical Use]
The selective inhibition of the type 2 5α-reductase isozyme produces a rapid reduction in plasma
DHT concentration, reaching 65% suppression within 24 hours of administering a 1-mg oral tablet
(106). At steady state, finasteride suppresses DHT levels by approximately 70% in plasma and by as
much as 85 to 90% in the prostate. The remaining DHT in the prostate likely is the result of type 1
5α-reductase. The mean circulating levels of testosterone and estradiol remained within their physiological concentration range. Long-term
therapy with finasteride can reduce clinical significant end points of BPH, such as acute urinary
retention or surgery. Finasteride is most effective in men with large prostates. Finasteride has no
affinity for the AR and no androgenic, antiandrogenic, estrogenic, antiestrogenic, or progestational
effects. | [Veterinary Drugs and Treatments]
Finasteride may be useful in treating the benign prostatic hypertrophy
in canine patients. Because of the drug’s relative expense and
the long duration of therapy required to see a response, its usefulness
may be limited in veterinary medicine.
It may also be useful in the adjunctive treatment of adrenal disease
in ferrets. | [Drug interactions]
Potentially hazardous interactions with other drugs
None known | [Metabolism]
Finasteride is metabolised primarily via the cytochrome
P450 3A4 enzyme subfamily. Following an oral dose
of 14C-finasteride in man, two metabolites of the drug
were identified that possess only a small fraction of the
5α-reductase inhibitory activity of finasteride. 39% of the
dose was excreted in the urine in the form of metabolites
(virtually no unchanged drug was excreted in the urine)
and 57% of total dose was excreted in the faeces. | [storage]
Store at RT | [References]
Perifollicular fibrosis: Pathogenetic role in androgenetic alopecia; H.G. Yoo, et al.; Biol. Pharm. Bull. 29, 1246 (2006). DOI:10.1248/BPB.29.1246
Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line: J.M. Golbano, et al.; Int. J. Oncol. 32, 919 (2008) DOI:10.3892/IJO.32.4.919
Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders: S. Paba, et al.; Curr. Pharm. Des. 17, 151 (2011) DOI:10.2174/138161211795049589
Finasteride: An update of its use in the management of symptomatic benign prostatic hyperplasia (a review). M. I. Wilde, K. L. Goa, Drugs 1999, 57, 557. DOI:10.2165/00003495-199957040-00008
Finasteride: a review of its use in male pattern hair loss. K. J. McClellan, A. Markham, Drugs 1999, 57, 111. DOI:10.2165/00003495-199957010-00014
Type 1 and type 2 5α-reductase expression in the development and progression of prostate cancer (a review). L. N. Thomas, R. C. Douglas, C. B. Lazier, C. K. L. Too, R. S. Rittmaster, D. J. Tindall, Eur. Urol. 2008, 53, 244. DOI:10.1016/J.EURURO.2007.10.052 |
|
|